Payment overview · 2025
General Payments
$268.46
29 reported records · 4 companies
Healthcare provider profile · identity verified
Robert Daniel Bennett, MD
Allopathic & Osteopathic Physicians|Family Medicine · VALDOSTA, GA · NPI 1023456290
Verified facts
What the public records show
CMS Open Payments records show Robert Daniel Bennett, MD received $268.46 in general payments during 2025 across 29 reported records.
Amgen Inc. accounted for 75.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $203.79 | 75.9% | 25 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.92 | 11.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.75 | 7.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.00 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $268.46 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $203.79 | 25 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $172.39 | 20 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
61 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
202 | 56 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
203 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 668 | 201 |
| Levothyroxine Sodium | Levothyroxine Sodium | 499 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 491 | 151 |
| Losartan Potassium | Losartan Potassium | 372 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 346 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 329 | 103 |
| Gabapentin | Gabapentin | 266 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 266 | 69 |
| Lisinopril | Lisinopril | 230 | 81 |
| Montelukast Sodium | Montelukast Sodium | 230 | 59 |
| Omeprazole | Omeprazole | 217 | 56 |
| Famotidine | Famotidine | 215 | 73 |
| Tramadol Hcl | Tramadol Hcl | 209 | 45 |
| Potassium Chloride | Potassium Chloride | 206 | 61 |
| Eliquis | Apixaban | 203 | 42 |
| Ozempic | Semaglutide | 202 | 56 |
| Metformin Hcl | Metformin Hcl | 194 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 73 |
| Prednisone | Prednisone | 165 | 130 |
| Carvedilol | Carvedilol | 145 | 46 |
| Mounjaro | Tirzepatide | 141 | 32 |
| Pregabalin | Pregabalin | 141 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 43 |
| Furosemide | Furosemide | 124 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 120 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 31 |
| Trazodone Hcl | Trazodone Hcl | 117 | 38 |
| Meloxicam | Meloxicam | 116 | 52 |
| Buspirone Hcl | Buspirone Hcl | 115 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 35 |
| Alprazolam | Alprazolam | 107 | 29 |
| Ondansetron Odt | Ondansetron | 105 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 31 |
| Sertraline Hcl | Sertraline Hcl | 99 | 38 |
| Spironolactone | Spironolactone | 99 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 41 |
| Bupropion Xl | Bupropion Hcl | 92 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 38 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 88 | 29 |
| Simvastatin | Simvastatin | 88 | 26 |
| Farxiga | Dapagliflozin Propanediol | 86 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 22 |
| Myrbetriq | Mirabegron | 78 | 19 |
| Allopurinol | Allopurinol | 77 | 28 |
| Baclofen | Baclofen | 77 | 31 |
| Januvia | Sitagliptin Phosphate | 76 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 76 | 60 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 75 | 28 |
| Glipizide | Glipizide | 75 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 23 |
| Azithromycin | Azithromycin | 72 | 64 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 71 | 70 |
| Clonazepam | Clonazepam | 71 | 14 |
| Jardiance | Empagliflozin | 70 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 24 |
| Synthroid | Levothyroxine Sodium | 67 | 17 |
| Trulicity | Dulaglutide | 67 | 17 |
| Repatha Sureclick | Evolocumab | 64 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 63 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 63 | 24 |
| Celecoxib | Celecoxib | 61 | 23 |
| Linzess | Linaclotide | 61 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 17 |
| Alendronate Sodium | Alendronate Sodium | 60 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 54 |
| Mirtazapine | Mirtazapine | 54 | 16 |
| Cephalexin | Cephalexin | 53 | 51 |
| Ezetimibe | Ezetimibe | 53 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 11 |
| Sucralfate | Sucralfate | 53 | 22 |
| Lorazepam | Lorazepam | 51 | 20 |
| Warfarin Sodium | Warfarin Sodium | 51 | 11 |
| Atenolol | Atenolol | 50 | 14 |
| Glipizide Er | Glipizide | 50 | 17 |
| Metformin Hcl Er | Metformin Hcl | 50 | 19 |
| Promethazine Hcl | Promethazine Hcl | 49 | 11 |
| Finasteride | Finasteride | 47 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | suppressed |
| Fluconazole | Fluconazole | 45 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 35 |
| Meclizine Hcl | Meclizine Hcl | 42 | 22 |
| Eszopiclone | Eszopiclone | 40 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 20 |
| Ibandronate Sodium | Ibandronate Sodium | 38 | 11 |
| Mupirocin | Mupirocin | 38 | 30 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 15 |
| Glimepiride | Glimepiride | 36 | 11 |
| Ibuprofen | Ibuprofen | 36 | 12 |
| Temazepam | Temazepam | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 29 |
| Valsartan | Valsartan | 35 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Torsemide | Torsemide | 34 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Topiramate | Topiramate | 30 | 13 |
| Sulindac | Sulindac | 29 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Levetiracetam | Levetiracetam | 27 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 14 |
| Estradiol | Estradiol | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Belsomra | Suvorexant | 23 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Repatha Syringe | Evolocumab | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 14 |
| Valacyclovir | Valacyclovir Hcl | 22 | 13 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 21 | 12 |
| Rybelsus | Semaglutide | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 14 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Clonidine | Clonidine | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Indomethacin | Indomethacin | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | 13 |
| Epinephrine | Epinephrine | 13 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $268.46 · 29 records | Amgen Inc. | NURTEC ODT, OTEZLA, REPATHA, UBRELVY, Wegovy, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error